CA2281570A1 - Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents - Google Patents

Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents Download PDF

Info

Publication number
CA2281570A1
CA2281570A1 CA002281570A CA2281570A CA2281570A1 CA 2281570 A1 CA2281570 A1 CA 2281570A1 CA 002281570 A CA002281570 A CA 002281570A CA 2281570 A CA2281570 A CA 2281570A CA 2281570 A1 CA2281570 A1 CA 2281570A1
Authority
CA
Canada
Prior art keywords
composition
shark cartilage
neoplastic agents
treating tumors
tumors containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002281570A
Other languages
French (fr)
Other versions
CA2281570C (en
Inventor
Eric Dupont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris Inc
Original Assignee
Les Laboratoires Aeterna Inc.
Eric Dupont
Aeterna Zentaris Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Aeterna Inc., Eric Dupont, Aeterna Zentaris Inc. filed Critical Les Laboratoires Aeterna Inc.
Priority to CA 2281570 priority Critical patent/CA2281570C/en
Publication of CA2281570A1 publication Critical patent/CA2281570A1/en
Application granted granted Critical
Publication of CA2281570C publication Critical patent/CA2281570C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention describes a novel use for cartilage extract, namely a shark cartilage extract, in a combined anti-timor therapy. The cartilage extract is used in combination with anti-neoplastics. The combined therapy provides for a higher anti-tumor efficacy with no concomitant increase, even better with a decrease, of toxic side effects.
CA 2281570 1997-03-11 1998-03-11 Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents Expired - Fee Related CA2281570C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2281570 CA2281570C (en) 1997-03-11 1998-03-11 Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2,199,694 1997-03-11
CA2199694 1997-03-11
CA 2281570 CA2281570C (en) 1997-03-11 1998-03-11 Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents
PCT/CA1998/000202 WO1998040088A1 (en) 1997-03-11 1998-03-11 Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents

Publications (2)

Publication Number Publication Date
CA2281570A1 true CA2281570A1 (en) 1998-09-17
CA2281570C CA2281570C (en) 2003-09-23

Family

ID=4160148

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2281570 Expired - Fee Related CA2281570C (en) 1997-03-11 1998-03-11 Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents

Country Status (19)

Country Link
US (2) US6383522B1 (en)
EP (1) EP0967987B1 (en)
JP (1) JP2001500899A (en)
KR (1) KR100417612B1 (en)
CN (2) CN1245993C (en)
AT (1) ATE241993T1 (en)
AU (1) AU745769B2 (en)
BR (1) BR9808858A (en)
CA (1) CA2281570C (en)
DE (1) DE69815310T2 (en)
DK (1) DK0967987T3 (en)
ES (1) ES2200316T3 (en)
HK (1) HK1026364A1 (en)
IL (1) IL131701A (en)
NO (1) NO322847B1 (en)
NZ (1) NZ337376A (en)
PT (1) PT967987E (en)
RU (1) RU2195946C2 (en)
WO (1) WO1998040088A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838466B2 (en) 2001-12-20 2005-01-04 Schering Corporation Compounds for the treatment of inflammatory disorders
US9278914B2 (en) 2004-06-07 2016-03-08 University Of Tennessee Research Foundation SARMs and method of use thereof
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US11090283B2 (en) 2007-09-11 2021-08-17 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
JP2005508322A (en) * 2001-09-24 2005-03-31 ジェシー エル エス オウ Methods and ingredients for determining the chemosensitized dose of suramin used in combination therapy
US20070010430A1 (en) * 2003-03-20 2007-01-11 Hosokawa Micron Corparation Proteoglycan isolated from cartilaginous fish and process for producing the same
WO2006059236A2 (en) * 2004-11-16 2006-06-08 Aeterna Zentaris Inc. Method of using cartilage extract for increasing blood parameters
PL1912675T3 (en) 2005-07-25 2014-10-31 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
EP1930017B1 (en) 2005-09-29 2012-05-23 Maruha Nichiro Seafoods, Inc. Composition effective for prevention and treatment of adult disease
MX363905B (en) * 2006-06-12 2019-04-08 Aptevo Res & Development Llc Single-chain multivalent binding proteins with effector function.
AU2008287195A1 (en) * 2007-07-06 2009-02-19 Emergent Product Development Seattle, Llc Binding peptides having a C-terminally disposed specific binding domain
WO2009126944A1 (en) * 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
JP7002446B2 (en) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー CD3 binding polypeptide
WO2017201200A1 (en) * 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28093E (en) 1962-02-28 1974-07-30 Wound-healing cartilage powder
US3478146A (en) 1965-02-26 1969-11-11 Leslie L Balassa Wound-healing cartilage powder extracting process
US3966908A (en) 1973-11-29 1976-06-29 Lescarden Ltd. Method of treating degenerative joint afflictions
US4042457A (en) 1975-11-10 1977-08-16 Rush-Presbyterian-St. Luke's Medical Center Preparation of tissue invasion inhibitor and method of treatment utilizing the inhibitor
US4822607A (en) 1976-10-29 1989-04-18 Lescarden Ltd. Anti-tumor agent and method
US4212857A (en) 1976-10-29 1980-07-15 Lescarden Ltd. Method for stimulating the production of immunoglobulin and total complement
US4243582A (en) 1979-04-26 1981-01-06 Monsanto Company Novel glycoproteins from bovine cartilage
US4350682A (en) 1979-05-11 1982-09-21 Lescarden Ltd. Cartilage extraction processes and products
US4356261A (en) 1980-04-22 1982-10-26 Rush-Presbyterian-St. Luke's Medical Center Anti-invasion factor containing cultures
US4456589A (en) 1982-07-08 1984-06-26 Genetic Laboratories, Inc. Preparation of animal tissues for surgical implantation in human recipients
US4473551A (en) 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
JPS5939828A (en) 1982-08-28 1984-03-05 Ajinomoto Co Inc Preparation of antitumor active substance
US4444752A (en) 1982-09-13 1984-04-24 Lescarden Ltd. Method for treating progressive systemic sclerosis
US4469676A (en) 1983-06-21 1984-09-04 Michel Hecmati Method for eliminating wrinkles occurring in the human skin
JPS60178820A (en) 1984-02-22 1985-09-12 Ajinomoto Co Inc Preparation of antitumor active substance
US4656137A (en) 1985-09-12 1987-04-07 Lescarden Inc Method of processing animal cartilage
US4749522A (en) 1985-10-31 1988-06-07 Angio-Medical Corporation Supercritical fluid extraction of animal derived materials
US4746729A (en) 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5096892A (en) 1988-05-27 1992-03-17 The Children's Medical Center Corporation Arylsulfatase inhibition and potentiation of angiostatic steroids and heparin
US5075112A (en) 1990-02-12 1991-12-24 Cartilage Technologies Inc. Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
CA2100657A1 (en) 1991-11-15 1993-05-16 Glen M. Hartung Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
WO1994012510A1 (en) 1992-11-30 1994-06-09 Lane I William Processing shark cartilage
EP2226085B1 (en) 1993-07-19 2013-11-27 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US6025334A (en) * 1994-04-28 2000-02-15 Les Laboratoires Aeterna Inc. Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
US5618925A (en) 1994-04-28 1997-04-08 Les Laboratories Aeterna Inc. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
US6028118A (en) 1996-08-08 2000-02-22 Les Laboratoires Aeterna Inc. Methods of using extracts of shark cartilage
US5583153A (en) 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
RO117590B1 (en) * 1995-02-03 2002-05-30 Aeterna Lab Inc Composition for treating a degeneration, a collagenic or inflammatory disease
US5843920A (en) 1996-09-16 1998-12-01 Biocell Technology, Llc Anionic saccharides for extraction of anti-angiogenic protein from cartilage
US6168807B1 (en) 1998-07-23 2001-01-02 Les Laboratoires Aeterna Inc. Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838466B2 (en) 2001-12-20 2005-01-04 Schering Corporation Compounds for the treatment of inflammatory disorders
US7034057B2 (en) 2001-12-20 2006-04-25 Schering Corporation Compounds for the treatment of inflammatory disorders
US7598242B2 (en) 2001-12-20 2009-10-06 Schering Corporation Compounds for the treatment of inflammatory disorders
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9278914B2 (en) 2004-06-07 2016-03-08 University Of Tennessee Research Foundation SARMs and method of use thereof
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US10053418B2 (en) 2004-06-07 2018-08-21 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US10662148B2 (en) 2004-06-07 2020-05-26 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10300037B2 (en) 2006-08-24 2019-05-28 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US11090283B2 (en) 2007-09-11 2021-08-17 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)

Also Published As

Publication number Publication date
NO994274L (en) 1999-11-09
US6383522B1 (en) 2002-05-07
CN1824317A (en) 2006-08-30
KR20000075929A (en) 2000-12-26
AU6605598A (en) 1998-09-29
NZ337376A (en) 2002-02-01
PT967987E (en) 2003-10-31
KR100417612B1 (en) 2004-02-05
US20020146462A1 (en) 2002-10-10
US6855338B2 (en) 2005-02-15
BR9808858A (en) 2000-08-01
ES2200316T3 (en) 2004-03-01
NO994274D0 (en) 1999-09-02
AU745769B2 (en) 2002-03-28
WO1998040088A1 (en) 1998-09-17
EP0967987B1 (en) 2003-06-04
IL131701A (en) 2005-03-20
JP2001500899A (en) 2001-01-23
IL131701A0 (en) 2001-03-19
EP0967987A1 (en) 2000-01-05
ATE241993T1 (en) 2003-06-15
HK1026364A1 (en) 2000-12-15
CA2281570C (en) 2003-09-23
CN1250375A (en) 2000-04-12
DE69815310D1 (en) 2003-07-10
DK0967987T3 (en) 2003-09-22
RU2195946C2 (en) 2003-01-10
NO322847B1 (en) 2006-12-11
DE69815310T2 (en) 2004-04-22
CN1245993C (en) 2006-03-22

Similar Documents

Publication Publication Date Title
CA2281570A1 (en) Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
ZA971259B (en) Antimicrobial peptides and methods of use.
MX9702415A (en) Antineoplastic cocoa extracts, methods for making, using.
ZA971009B (en) Synergistic antimicrobial compositions containing an ionene polymer and a salt of dodecylamine and methods of using the same.
WO2002076499A3 (en) Combination treatment of pancreatic cancer
HK1020259A1 (en) Composition for use in the treatment and prevention of hyperuricemia.
CA2340728A1 (en) Methods of treating hypertension and compositions for use therein
IL134937A0 (en) Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
ZA988941B (en) Conjugated polypeptides for treating Herpes Simples virus, compositions and vaccines containing same and uses thereof for treatment or prevention of Herpes Simplex virus and as diagnostic tool and in diagnostic kit.
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
HUT71377A (en) Artificial tanning cosmetical compositions based on dihydroxyacetone, preparation and use of them
ZA97252B (en) Compositions for the prevention and treatment of osteoporosis.
GB9607568D0 (en) Antimicrobial hair treatment composition
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
EP0852503A4 (en) Composition for the treatment of diarrhea, its use and its preparation
BG104914A (en) Paroxetine maleate
GB9802542D0 (en) New use
HU9600727D0 (en) Triaryl-ethylene derivatives for use in therapy
EP0673640A4 (en) Intermediate permanent wave treatment composition.
HU9903098D0 (en) Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
CA2309653A1 (en) Use of protein h as cytostatic agent
EP1842538A3 (en) Treatment for Raynaud's Phenomenon
EP1447089A3 (en) Methods of treating hypertension and compositions for use therein

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed